NCT03764787 (I-HypoPT) is a Phase 1, PHASE2 clinical trial of Radiation+PD-1 Ab in Proton Therapy, sponsored by Peking University First Hospital.

Who is sponsoring NCT03764787?

NCT03764787 is sponsored by Peking University First Hospital.

What drugs are being tested in NCT03764787?

Interventions in NCT03764787: Radiation+PD-1 Ab.

What condition does NCT03764787 study?

NCT03764787 studies Proton Therapy, Immunotherapy.

Is NCT03764787 still recruiting?

NCT03764787 is currently status unknown. Last updated 5 December 2018.

Last reviewed 2018-12-05 · How we verify

NCT03764787: I-HypoPT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination of Hypofractionated Proton Therapy With Immunotherapy

Status unknown Phase 1, PHASE2 Last updated 5 December 2018

What this trial tests

Phase 1, PHASE2 trial testing Radiation+PD-1 Ab in Proton Therapy in 30 participants. Status unknown.

Timeline

1 January 2019

Primary endpoint
1 January 2021

1 December 2021

Quick facts

Lead sponsor	Peking University First Hospital
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 January 2019
Primary completion	1 January 2021
Estimated completion	1 December 2021

Drugs / interventions tested

Radiation+PD-1 Ab

Conditions studied

Proton Therapy — all drugs for Proton Therapy →
Immunotherapy — all drugs for Immunotherapy →

Sponsor

Peking University First Hospital

Who can join

18 and older, any sex, with Proton Therapy or Immunotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to compare the effects (good and bad) on subjects and their cancer using hypofractionated proton radiation therapy in combination with immunotherapy(ie. Programmed cell death protein 1, also known as PD-1 antibody). Hypofractionation is a technique that delivers higher daily doses of radiation over a shorter period of time.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Impact of proton therapy on antitumor immune response.
Mirjolet C, Nicol A, Limagne E, Mura C, et al · · 2021 · cited 39× · PMID 34188135 · DOI 10.1038/s41598-021-92942-1
Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy.
Marcus D, Lieverse RIY, Klein C, Abdollahi A, et al · · 2021 · cited 33× · PMID 33806808 · DOI 10.3390/cancers13061468
Distinct immune responses to proton and photon radiotherapy: implications for anti-PD-L1 combination therapy in colorectal cancer.
Burckel H, Nicol A, Mura C, Rousseau M, et al · · 2025 · cited 1× · PMID 40122794 · DOI 10.1186/s12967-025-06377-7
Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies.
Ge Q, Yu L, Lu J, Anwaier A, et al · · 2026 · PMID 42164656 · DOI 10.1002/mco2.70771

Verify or expand the search:

Other recruiting trials for Proton Therapy

Currently open trials in the same condition.

NCT06826885 — Safety and Efficacy of IMPT or IMRT for Breast Cancer · recruiting
NCT07135661 — Ultra-Hypofractionated vs. Moderately Hypofractionated Proton Therapy for Early Breast Cancer After Lumpectomy · NA · recruiting
NCT06462378 — Proton Therapy for Locally Advanced Cervical Cancer · Phase 2 · recruiting
NCT05364411 — HYpofractionated, Dose-redistributed RAdiotherapy With Protons and Photons in HNSCC · NA · recruiting
NCT05055648 — PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy · Phase 3 · recruiting

Other Peking University First Hospital trials

Trials by the same sponsor.

NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
NCT07517276 — TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index · Phase 2 · not yet recruiting
NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
NCT07464119 — A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy · NA · not yet recruiting
NCT07460843 — Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03764787 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University First Hospital
Last refreshed: 5 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03764787.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing